Study shows downward trend in Sovaldi utilization

September 17, 2014 12:46 PM

3 0

Study shows downward trend in Sovaldi utilization

(Reuters) - Over the last several months there has been a 'plateau and downward trend' in the use of Gilead Sciences Inc's controversial $1,000-a-pill hepatitis C treatment, Sovaldi, a CVS Health Corp analysis showed.

The study, encompassing data from May through August 2014, suggests that another surge of patients will begin therapy when newer treatments of similar effectiveness and shorter duration are introduced later in the year.

Also read: House Passes Health Bill to Speed Drug Approvals, Boost Biomedical Research

Read more

To category page

Loading...